OTCs and arthritis
This article was originally published in The Tan Sheet
Recent NSAID publicity has affected the way 82% of orthopedic surgeons recommend pain relievers, according to the results of a telephone survey by Florida Hospital and the Joint Replacement Center released Aug. 10. The survey, which polled 259 specialists between June 16 and July 7, reports that 70% of orthopedic surgeons prescribe OTC medication for minor arthritis pain rather than Rx drugs. Of the group, 58% prefer Aleve, 35% recommend Advil and 7% suggest Tylenol as the first line of treatment against arthritis pain. Aleve ranked No. 1 for its "easy dosing" with "fewer pills" and long-lasting relief. The survey measured how surgeons are reacting to new NSAID data and reports that 90% of orthopedic surgeons have decreased prescribing COX-2 inhibitors in favor of OTCs...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”